Shares of BioAmber Inc. (NYSE:BIOA) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus price target of $10.35 for the company and are predicting that the company will post ($0.22) EPS for the current quarter, according to Zacks. Zacks has also assigned BioAmber an industry rank of 81 out of 265 based on the ratings given to its competitors.
BIOA has been the topic of several research reports. Canaccord Genuity reiterated a “buy” rating and issued a $5.50 price objective on shares of BioAmber in a report on Sunday, August 7th. Zacks Investment Research upgraded shares of BioAmber from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th.
BioAmber (NYSE:BIOA) traded down 1.32% during trading on Friday, hitting $4.50. 53,573 shares of the stock were exchanged. The firm has a 50-day moving average of $3.86 and a 200-day moving average of $3.73. BioAmber has a 52 week low of $2.86 and a 52 week high of $8.92. The stock’s market capitalization is $129.76 million.
BioAmber (NYSE:BIOA) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.25) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. BioAmber had a negative net margin of 381.99% and a negative return on equity of 65.99%. The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.37 million. Equities research analysts anticipate that BioAmber will post ($0.73) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in BioAmber stock. Royce & Associates LP increased its stake in BioAmber Inc. (NYSE:BIOA) by 4.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 964,879 shares of the company’s stock after buying an additional 43,000 shares during the period. Royce & Associates LP owned 3.73% of BioAmber worth $4,052,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.10% of the company’s stock.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.